Randomized Placebo-Controlled Trial of Glutamine for Patients with IBS

谷氨酰胺治疗 IBS 患者的随机安慰剂对照试验

• 批准号: 9127707
• 负责人: George Nicholas Verne
• 金额: $ 10.94万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-08-15 至 2016-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9127707
• 关键词: Randomized; Placebo; Controlled; Trial; Glutamine

G. Nicholas Verne, M.D. Revision to Grant # AT005291 PROJECT SUMMARY Irritable bowel syndrome (IBS) is a common gastrointestinal disorder that is estimated to affect 20% of the US population. IBS patients have significantly decreased quality of life and utilize large amounts of health care resources. IBS patients suffer from chronic abdominal pain associated with diarrhea, constipation, and/or bloating (Verne & Cerda, 1997). Several mechanisms that may lead to IBS have been proposed including: alterations in receptors and neuropeptides, bacterial overgrowth and altered microbiota, altered intestinal transit, anxiety and depressive symptoms, and increased intestinal membrane permeability. Several recent studies have shown that diarrhea-predominant IBS (D-IBS) patients have increased intestinal permeability that may lead to chronic gastrointestinal symptoms (Dunlop et al., 2006; Spiller 2000; 2007; Zhou et al., 2009b). Our laboratory recently evaluated diarrhea-predominant IBS patients and reported that they have increased membrane permeability (Zhou et al, 2009). We now have obtained preliminary evidence that oral glutamine supplementation restores membrane permeability and improves chronic gastrointestinal symptoms in these IBS patients. Based on these new findings, we hypothesize that oral glutamine supplementation will improve the IBS Symptom Severity Scale and restore intestinal membrane permeability in diarrhea-predominant IBS patients. We propose to conduct a randomized, double-blind, placebo-controlled clinical trial studying glutamine 10 g po tid compared to placebo 10 g po tid for 8 weeks in 100 diarrhea-predominant IBS patients. The IBS Symptom Severity Scale and intestinal membrane permeability will be measured at baseline, 2, 4, 6, and at 8 weeks.

G.尼古拉斯·凡尔纳，医学博士批准号AT005291修订

项目成果

Neurogastroenterology: Neuronal correlates of placebo in chronic FGIDs.

• DOI: 10.1038/nrgastro.2014.118
• 发表时间: 2014-08
• 期刊: Nature reviews. Gastroenterology & hepatology
• 作者: Zhou Q;Verne GN
• 通讯作者: Verne GN

MicroRNA 29 targets nuclear factor-κB-repressing factor and Claudin 1 to increase intestinal permeability.

• DOI: 10.1053/j.gastro.2014.09.037
• 发表时间: 2015-01
• 期刊: Gastroenterology
• 影响因子: 29.4
• 作者: Zhou Q;Costinean S;Croce CM;Brasier AR;Merwat S;Larson SA;Basra S;Verne GN
• 通讯作者: Verne GN

Intestinal barrier function in health and gastrointestinal disease.

• DOI: 10.1111/j.1365-2982.2012.01921.x
• 发表时间: 2012-06
• 期刊: Neurogastroenterology and motility
• 影响因子: 3.5
• 作者: Camilleri M;Madsen K;Spiller R;Greenwood-Van Meerveld B;Verne GN
• 通讯作者: Verne GN

Reply: To PMID 25277410.

回复：PMID 25277410。

• DOI: 10.1053/j.gastro.2015.03.030
• 发表时间: 2015
• 期刊: Gastroenterology
• 影响因子: 29.4
• 作者: Zhou,QiQi;Verne,GNicholas
• 通讯作者: Verne,GNicholas

Role of microRNA in chronic visceral nociception.

• DOI: 10.1016/j.pain.2012.10.015
• 发表时间: 2013-01
• 期刊: Pain
• 影响因子: 7.4
• 作者: Zhou Q;Verne NG
• 通讯作者: Verne NG